Business Description
Sanofi SA
ISIN : FR0000120578
Total Employee Number:
74,846Compare
Compare
Traded in other countries / regions
SAN.FranceSNY.USA0O59.UKSNW.GermanySAN1N.Mexico1SAN.ItalySAN.CanadaSANO.AustriaSNW.BulgariaSAN.Switzerland IPO Date
2007-12-28Description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.42 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.29 | |||||
Debt-to-EBITDA | 1.63 | |||||
Interest Coverage | 15.33 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 1.55 | |||||
Beneish M-Score | -2.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.7 | |||||
3-Year EBITDA Growth Rate | -1.8 | |||||
3-Year EPS without NRI Growth Rate | -2.9 | |||||
3-Year FCF Growth Rate | -4.2 | |||||
3-Year Book Growth Rate | -0.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 7.56 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.13 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
6-1 Month Momentum % | -5.98 | |||||
12-1 Month Momentum % | 7.77 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.09 | |||||
Quick Ratio | 0.73 | |||||
Cash Ratio | 0.3 | |||||
Days Inventory | 272.84 | |||||
Days Sales Outstanding | 62.24 | |||||
Days Payable | 205 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 5.6 | |||||
3-Year Average Share Buyback Ratio | 1.4 | |||||
Shareholder Yield % | 10.46 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.07 | |||||
Operating Margin % | 20.54 | |||||
Net Margin % | 16.72 | |||||
EBITDA Margin % | 26.71 | |||||
FCF Margin % | 15.43 | |||||
OCF Margin % | 23 | |||||
ROE % | 10.71 | |||||
ROA % | 6.09 | |||||
ROIC % | 7.04 | |||||
3-Year ROIIC % | -12.01 | |||||
ROC (Joel Greenblatt) % | 49.6 | |||||
ROCE % | 6.85 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.78 | |||||
Forward PE Ratio | 9.53 | |||||
PE Ratio without NRI | 11.99 | |||||
Shiller PE Ratio | 12.98 | |||||
Price-to-Owner-Earnings | 8.68 | |||||
PS Ratio | 1.97 | |||||
PB Ratio | 1.27 | |||||
Price-to-Tangible-Book | 23.77 | |||||
Price-to-Free-Cash-Flow | 12.77 | |||||
Price-to-Operating-Cash-Flow | 8.57 | |||||
EV-to-EBIT | 15.39 | |||||
EV-to-Forward-EBIT | 10.07 | |||||
EV-to-EBITDA | 8.39 | |||||
EV-to-Forward-EBITDA | 8.29 | |||||
EV-to-Revenue | 2.24 | |||||
EV-to-Forward-Revenue | 2.09 | |||||
EV-to-FCF | 14.51 | |||||
Price-to-GF-Value | 0.7 | |||||
Price-to-Projected-FCF | 0.75 | |||||
Price-to-Median-PS-Value | 0.7 | |||||
Price-to-Graham-Number | 3.56 | |||||
Earnings Yield (Greenblatt) % | 6.5 | |||||
FCF Yield % | 8.03 | |||||
Forward Rate of Return (Yacktman) % | 2.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Sanofi SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 43,695.107 | ||
| EPS (TTM) (CHF) | 5.967 | ||
| Beta | -0.0783 | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.02 | ||
| Volatility % | 15.28 | ||
| 14-Day RSI | - | ||
| 14-Day ATR (CHF) | - | ||
| 20-Day SMA (CHF) | 73.2 | ||
| 12-1 Month Momentum % | 7.77 | ||
| 52-Week Range (CHF) | 73.2 - 73.2 | ||
| Shares Outstanding (Mil) | 1,196.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sanofi SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sanofi SA Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 | In 125 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 125 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 | In 33 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | In 33 days | ||
| General meeting for 2026 | 2026-04-29 | 73.20 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-23 07:00 | 73.20 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 73.20 (+0.00%) | ||
| Annual report for 2025 | 2026-02-18 | -- | ||
| Fourth quarter earnings conference call for 2025 | 2026-01-29 08:30 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-01-29 | -- |
Show
Entries
Sanofi SA Frequently Asked Questions
What is Sanofi SA(XSWX:SAN)'s stock price today?
The current price of XSWX:SAN is CHF73.20. The 52 week high of XSWX:SAN is CHF73.20 and 52 week low is CHF73.20.
When is next earnings date of Sanofi SA(XSWX:SAN)?
The next earnings date of Sanofi SA(XSWX:SAN) is 2026-07-30.
Does Sanofi SA(XSWX:SAN) pay dividends? If so, how much?
Sanofi SA(XSWX:SAN) does not pay dividend.
Press Release
Articles on Sanofi SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers